Fischbach Peter S, White Andrew, Barrett Terrance D, Lucchesi Benedict R
Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI 48109-0204, USA.
J Pharmacol Exp Ther. 2004 May;309(2):554-9. doi: 10.1124/jpet.103.060780. Epub 2004 Jan 27.
Myocardial ATP-gated potassium channels (K-ATPs) are critical in the intracellular signaling cascade resulting in ischemic preconditioning (IP). Mitochondrial K-ATP channels seem to be responsible for IP, whereas the functions of K-ATP channels in the sarcolemmal membrane are less well understood. The proarrhythmic potential of specific versus nonspecific opening of K-ATP channels has not been investigated. In this study, Langendorff-perfused rabbit hearts were exposed to either pinacidil (1.25 microM), a nonselective K-ATP channel agonist, or selective mitochondrial or sarcolemmal K-ATP channel agonists or antagonists. The hearts were then subjected to 12 min of hypoxic perfusion and 40 min of reoxygenation. Hearts were monitored for the induction of ventricular fibrillation (VF). No heart subjected to hypoxia-reoxygenation without drug treatment developed VF (0 of 5). Pinacidil pretreatment induced VF (12 of 14; p = 0.004 versus control). Pinacidil's effect was blocked by HMR-1098 (1-[5-[2-(5-chloro-o-anisamide)ethyl]-2-methoxyphenyl]sulfonyl]-3-methylthiourea) (1 microM), a selective sarcolemmal K-ATP channel antagonist (1 of 7; p = 0.007 versus pinacidil; N.S. versus control). Hearts pretreated with 5-hydroxydecanoate (5-HD) (100 microM), a putatively selective mitochondrial K-ATP channel blocker developed VF in one of eight trials (N.S. versus control). 5-HD did not alter the effects of pinacidil (6 of 8; p < 0.05 versus control; N.S. versus pinacidil alone). Selective mitochondrial K-ATP channel activation with [(3R)-trans-4-((4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)dimethyl-2H-1-benzopyran-6-carbonitril monohydrochloride] (BMS-191095) (6 microM) resulted in zero of five hearts developing VF (N.S. versus control). Our data suggest that selective opening of the sarcolemmal K-ATP channel during hypoxia-reoxygenation induced VF, whereas opening of the mitochondrial channel was not associated with VF. The findings suggest that caution should be exercised when developing compounds aimed at inducing IP, and nonspecific opening of the K-ATP channel should be avoided.
心肌ATP敏感性钾通道(K-ATP)在导致缺血预处理(IP)的细胞内信号级联反应中起关键作用。线粒体K-ATP通道似乎是IP的原因,而肌膜上K-ATP通道的功能尚不太清楚。K-ATP通道特异性与非特异性开放的促心律失常潜力尚未得到研究。在本研究中,采用Langendorff灌注兔心脏,使其暴露于非选择性K-ATP通道激动剂吡那地尔(1.25微摩尔)、选择性线粒体或肌膜K-ATP通道激动剂或拮抗剂中。然后对心脏进行12分钟的低氧灌注和40分钟的复氧。监测心脏室颤(VF)的诱发情况。未经药物治疗而进行低氧-复氧的心脏未发生VF(5只中0只)。吡那地尔预处理诱发了VF(14只中12只;与对照组相比,p = 0.004)。吡那地尔的作用被HMR-1098(1-[5-[2-(5-氯-邻茴香酰胺)乙基]-2-甲氧基苯基]磺酰基]-3-甲基硫脲)(1微摩尔)阻断,HMR-1098是一种选择性肌膜K-ATP通道拮抗剂(7只中1只;与吡那地尔相比,p = 0.007;与对照组相比无统计学差异)。用5-羟基癸酸(5-HD)(100微摩尔)预处理的心脏,5-HD是一种公认的选择性线粒体K-ATP通道阻滞剂,在8次试验中有1次发生VF(与对照组相比无统计学差异)。5-HD未改变吡那地尔的作用(8只中6只;与对照组相比,p < 0.05;与单独使用吡那地尔相比无统计学差异)。用[(3R)-反式-4-((4-氯苯基)-N-(1H-咪唑-2-基甲基)二甲基-2H-1-苯并吡喃-6-腈一盐酸盐](BMS-191095)(6微摩尔)选择性激活线粒体K-ATP通道,5只心脏中有0只发生VF(与对照组相比无统计学差异)。我们的数据表明,在低氧-复氧期间选择性开放肌膜K-ATP通道可诱发VF,而线粒体通道开放与VF无关。这些发现表明,在开发旨在诱导IP的化合物时应谨慎,应避免K-ATP通道的非特异性开放。